Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need

Print Friendly, PDF & Email

RE: RENAL Health: Advancing Phase 2 and Phase 3 stud ies of the company’s targeted C3 therapy in C3G / IC-MPGN , rare kidney diseases with no approved medicines . First patient in Phase 2 study expected to be dosed by the end of th e year P otentially registrational Phase 2 […]